Patents Assigned to Roche GlycArt AG
-
Publication number: 20200079873Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.Type: ApplicationFiled: April 8, 2019Publication date: March 12, 2020Applicant: Roche Glycart AGInventors: Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMANA
-
Patent number: 10577429Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.Type: GrantFiled: March 18, 2015Date of Patent: March 3, 2020Assignee: ROCHE GLYCART AGInventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Patent number: 10562949Abstract: The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (IL-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: GrantFiled: September 5, 2017Date of Patent: February 18, 2020Assignee: Roche Glycart AGInventors: Ralf Hosse, Christian Klein, Ekkehard Moessner, Laurence Bernard Peterson, Pablo Umana, Linda Wicker
-
Publication number: 20190322763Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: ApplicationFiled: December 10, 2018Publication date: October 24, 2019Applicant: Roche Glycart AGInventors: Oliver AST, Peter BRUENKER, Thomas U. HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
-
Publication number: 20190322765Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: June 17, 2019Publication date: October 24, 2019Applicant: Roche Glycart AGInventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20190315883Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: ApplicationFiled: June 3, 2019Publication date: October 17, 2019Applicant: Roche Glycart AGInventors: Oliver AST, Peter BRUENKER, Thomas U. HOFER, Ralf HOSSE, Christian Klein, Ekkehard MOESSNER, Pablo UMANA
-
Patent number: 10352943Abstract: This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.Type: GrantFiled: June 10, 2016Date of Patent: July 16, 2019Assignee: Roche Glycart AGInventors: Christiane Jaeger, Hans Koll, Peter Sondermann, Pablo Umana
-
Publication number: 20190185583Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.Type: ApplicationFiled: February 28, 2019Publication date: June 20, 2019Applicant: Roche Glycart AGInventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
-
Patent number: 10323098Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: GrantFiled: January 15, 2016Date of Patent: June 18, 2019Assignee: ROCHE GLYCART AGInventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Patent number: 10316104Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: GrantFiled: January 15, 2016Date of Patent: June 11, 2019Assignee: ROCHE GLYCART AGInventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
-
Publication number: 20190169309Abstract: Herein is reported a multi-function protein, characterized in that it comprises exactly one antigen presenting domain, exactly one antibody Fc-region, and at least one antigen binding site, wherein the antigen presenting domain comprises in N- to C-terminal direction either (i) a ?2-microglobulin, and (ii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of less than 1%, or (i) a T-cell response eliciting peptide, (ii) a ?2-microglobulin, and (iii) the extracellular domains ?1, ?2, and ?3 of a class I MHC molecule with a relative frequency of 1% or more, wherein the antigen binding site binds to a cancer cell surface antigen.Type: ApplicationFiled: July 30, 2018Publication date: June 6, 2019Applicant: Roche Glycart AGInventors: Christian Klein, Hendrik Knoetgen, Martina Schmittnaegel, Pablo Umana
-
Patent number: 10253110Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.Type: GrantFiled: March 18, 2015Date of Patent: April 9, 2019Assignee: ROCHE GLYCART AGInventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20190077881Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: ApplicationFiled: November 21, 2018Publication date: March 14, 2019Applicant: Roche Glycart AGInventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Publication number: 20190062453Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 6, 2018Publication date: February 28, 2019Applicant: Roche Glycart AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, lnja Waldhauer, Huisheng Wang, Barbara Weiser
-
Patent number: 10202464Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.Type: GrantFiled: July 1, 2016Date of Patent: February 12, 2019Assignee: ROCHE GLYCART AGInventors: Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
-
Patent number: 10196456Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: February 17, 2017Date of Patent: February 5, 2019Assignee: Roche Glycart AGInventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
-
Publication number: 20190031760Abstract: The present invention generally relates to antibodies specific for asialoglycoprotein receptor (ASGPR) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies of the invention, and to methods of using them in the treatment of disease.Type: ApplicationFiled: September 14, 2018Publication date: January 31, 2019Applicant: ROCHE GLYCART AGInventors: Thomas HOFER, Changhua Ji, Ekkehard Moessner, Pablo Umana
-
Patent number: 10184009Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.Type: GrantFiled: December 20, 2017Date of Patent: January 22, 2019Assignee: ROCHE GLYCART AGInventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
-
Patent number: 10155815Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: February 24, 2014Date of Patent: December 18, 2018Assignee: Roche Glycart AGInventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Neumann, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
-
Patent number: 10106600Abstract: The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: March 24, 2011Date of Patent: October 23, 2018Assignee: Roche Glycart AGInventors: Ulrich Brinkmann, Rebecca Croasdale, Harald Duerr, Christian Klein, Erhard Kopetzki, Wilma Lau, Joerg Thomas Regula, Juergen Michael Schanzer, Pablo Umana, Katharina Wartha